Key result
Elevated TMAO improves MACCE risk prediction incrementally beyond clinical variables and CT-FFR.
Why the study?
Physiological assessment by coronary CT angiography with CT-FFR does not fully capture patient-level cardiovascular risk, as adverse events occur in patients without functionally significant ischemia.
Does elevated serum TMAO predict major adverse cardiac and cerebrovascular events in patients undergoing coronary CT angiography with CT-FFR?
Cohort (n=3,978)
Does elevated serum TMAO predict major adverse cardiac and cerebrovascular events in patients undergoing coronary CT angiography with CT-FFR?
Elevated circulating TMAO provides complementary prognostic value for adverse cardiovascular events beyond anatomical and physiological assessment by coronary CTA and CT-FFR.
Answers are grounded in this paper and cite their sources.
May identify residual risk beyond CT-FFR in patients without ischemia; leaves open whether TMAO refines stratification or warrants intervention.
BACKGROUND: Coronary computed tomography (CT) angiography with CT-derived fractional flow reserve (CT-FFR) enables noninvasive identification of flow-limiting coronary stenosis and is widely used for risk assessment. However, adverse cardiovascular events still occur in a subset of patients without functionally significant ischemia, suggesting that physiological assessment alone may not fully capture patient-level risk. We aimed to evaluate whether circulating trimethylamine N-oxide (TMAO), a gut microbiota-derived biomarker, provides complementary prognostic information. METHODS: In this biobank-linked retrospective cohort study, 3978 patients undergoing clinically indicated coronary CT angiography with CT-FFR assessment were included. Serum TMAO concentrations were measured from cryopreserved samples obtained within ±30 days of imaging. Patients were stratified into high and low TMAO groups according to the receiver operating characteristic-derived threshold. The primary end point was major adverse cardiac and cerebrovascular events during a median follow-up of ∼3 years. Multivariable Cox models evaluated associations between TMAO and outcomes, and incremental prognostic value beyond clinical variables and CT-FFR was assessed. Addition of TMAO improved discrimination after bootstrap optimism correction (C-index 0.552-0.591). Among patients with preserved CT-FFR, elevated TMAO identified a subgroup with higher event rates, whereas patients with preserved CT-FFR and low TMAO had the most favorable prognosis. CONCLUSIONS: Physiological assessment and clinical outcomes are not synonymous in patients undergoing coronary CT angiography. Circulating TMAO provides complementary prognostic information and refines risk stratification, particularly among individuals without functionally significant ischemia. Integrating systemic biomarkers with coronary physiological assessment may improve individualized risk evaluation beyond imaging alone.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) conducted a cohort in Patients undergoing clinically indicated coronary CT angiography with CT-FFR assessment (n=3,978). High trimethylamine N-oxide (TMAO) concentration vs. Low TMAO concentration was evaluated on Major adverse cardiac and cerebrovascular events (p=<0.001). Elevated circulating TMAO provided incremental prognostic value for major adverse cardiac and cerebrovascular events beyond clinical variables and CT-FFR.
Synapse has enriched 10 related papers. Consider them for comparative context: